EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

NNMT-driven metabolic reprogramming creates a NAMPT druggable vulnerability and reveals liquid biopsy biomarkers for TKI resistance in EGFR-mutant NSCLC

I Pulido, J C García-Cañaveras, M L Rodríguez, J H Becker, A López, M Aupí, S Aparisi, L Chuliá-Peris, E Tamayo-Torres, C Carreres-Rey, J Alcácer Fernández-Coronado, M Benet und 16 weitere

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2025.218032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von I Pulido und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Cardiothoracic Surgery, USA; University of Illinois Hospital & Health Sciences System Cancer Center, University of…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Nicotinamide Phosphoribosyltransferase, Lung Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, INCLIVA Instituto de Investigación Sanitaria, European Regional Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer is the deadliest neoplasia worldwide. Despite the availability of targeted therapies like tyrosine kinase inhibitors (TKIs) for EGFR-driven tumours in Non-Small Cell Lung Cancer (NSCLC), drug resistance remains a major factor that dramatically cuts life expectancy. Here we identify how increased expression of nicotinamide N-methyltransferase (NNMT) in TKI-resistant cancer cells diverts nicotinamide to synthesise 1-Methylnicotinamide (1-MNA) and lowers NAD+ levels that generates a druggable nicotinamide phosphoribosyltransferase (NAMPT) metabolic vulnerability. We also report that high blood levels of 1-MNA, the by-product of NNMT activity, are significantly associated with lower survival rates in EGFR TKI-treated NSCLC patients. Taken together, our findings describe a new and highly specific non-genetic metabolic synthetic lethality for mesenchymal-like tumours, which exposes NAMPT as an in vivo druggable target and establishes 1-MNA as a novel liquid biopsy biomarker to predict and monitor EGFR TKI resistance in NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungNicotinamide PhosphoribosyltransferaseLung NeoplasmsDrug Resistance, NeoplasmProtein Kinase InhibitorsCytokinesNicotinamide N-MethyltransferaseHumansErbB ReceptorsMetabolic ReprogrammingBiomarkers, TumorLiquid BiopsyMutationAnimalsCell Line, Tumor

Stichwörter der Autor:innen

EGFRLiquid biopsyMetabolic rewiringNAMPTNNMTNSCLCTKIs

Substanzen

Nicotinamide PhosphoribosyltransferaseErbB ReceptorsProtein Kinase Inhibitorsnicotinamide phosphoribosyltransferase, humanCytokinesEGFR protein, humanBiomarkers, TumorNicotinamide N-MethyltransferaseNNMT protein, human

Autor:innen und Institutionen

  • Department of Surgery, Division of Cardiothoracic Surgery, USA; University of Illinois Hospital & Health Sciences System Cancer Center, University of Illinois Chicago, Chicago, IL, 60612, USA; Department of Physiology,…
  • Biomarkers and Precision Medicine Unit and Analytic Unit, Health Research Institute Hospital La Fe, Valencia, Spain.
  • Department of Physiology, Universitat de Valencia, Valencia, Spain.
  • Department of Surgery, Division of Cardiothoracic Surgery, USA; University of Illinois Hospital & Health Sciences System Cancer Center, University of Illinois Chicago, Chicago, IL, 60612, USA.
  • University of Illinois Hospital & Health Sciences System Cancer Center, University of Illinois Chicago, Chicago, IL, 60612, USA.
  • Department of Pathology, Hospital Quirónsalud, Valencia, Spain.

Förderung

  • Instituto de Salud Carlos III
  • INCLIVA Instituto de Investigación Sanitaria
  • European Regional Development Fund
  • Generalitat Valenciana
  • U.S. Department of Defense
  • Ministerio de Ciencia, Innovación y Universidades
  • Domingo Martínez Foundation
  • Ministerio de Ciencia e Innovación

Zitieren

APA

Pulido, I., García-Cañaveras, J. C., Rodríguez, M. L., Becker, J. H., López, A., Aupí, M., Aparisi, S., Chuliá-Peris, L., Tamayo-Torres, E., Carreres-Rey, C., Alcácer Fernández-Coronado, J., Benet, M., Montero, S., Mena, S., Sandoval, J., Pereda, J., Alcácer, J., Calabuig-Fariñas, S., Jantus-Lewintre, E., …, & Carretero, J. (2025). NNMT-driven metabolic reprogramming creates a NAMPT druggable vulnerability and reveals liquid biopsy biomarkers for TKI resistance in EGFR-mutant NSCLC. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.218032

Vancouver

Pulido I, García-Cañaveras JC, Rodríguez ML, Becker JH, López A, Aupí M, et al. NNMT-driven metabolic reprogramming creates a NAMPT druggable vulnerability and reveals liquid biopsy biomarkers for TKI resistance in EGFR-mutant NSCLC. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.218032

BibTeX
@article{Pulido2025,
  author = {Pulido, I and García-Cañaveras, J C and Rodríguez, M L and Becker, J H and López, A and Aupí, M and Aparisi, S and Chuliá-Peris, L and Tamayo-Torres, E and Carreres-Rey, C and Alcácer Fernández-Coronado, J and Benet, M and Montero, S and Mena, S and Sandoval, J and Pereda, J and Alcácer, J and Calabuig-Fariñas, S and Jantus-Lewintre, E and Cremades, A and Galbis-Caravajal, J M and Martín-Martorell, P and Insa, A and Massad, Malek G and Juan-Vidal, O and Lahoz, A and Shimamura, T and Carretero, J},
  title = {NNMT-driven metabolic reprogramming creates a NAMPT druggable vulnerability and reveals liquid biopsy biomarkers for TKI resistance in EGFR-mutant NSCLC},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2025.218032}
}
Kostenlos starten →